Cancer Diagnoses Covered for Bevacizumab (Avastin™)

Empire Medicare Services (EMS) will cover the use of bevacizumab in the treatment of patients with metastatic breast cancer, effective for dates of service on or after February 1, 2006.

This represents an expansion of coverage for bevacizumab by this carrier. Listed below are the current payable indications for this drug and the dates from which they are effective:

See separate article on bevacizumab for age-related macular degeneration (AMD).

© All current procedural terminology (CPT) codes and descriptors copyrighted by the American Medical Association.